Does donor iliac artery percutaneous transluminal angioplasty or stent placement influence the results of femorofemoral bypass? Analysis of 70 consecutive cases with long-term follow-up  by Perler, Bruce A. & Williams, G.M.
Does donor iliac artery percutaneous 
transluminal angioplasty or stent placement 
influence the results of femorofemoral bypass? 
Analysis of 70 consecutive cases with 
long-term follow-up 
Bruce A. Perler, MD,  and G. M. Williams, MD, Baltimore, Md. 
Purpose: Femorofemoral bypass procedures are being performed with increasing frequency 
ha some patients with bilateral disease in whom the "donor" iliac artery undergoes 
percutaneous transluminal ngioplasty or stent placement. This study was undertaken to 
critically examine the efficacy of this approach. 
Methods: The records of 70 consecutive patients who over a 14-year period underwent 
elective femorofemoral bypass procedures for chronic occlusive disease, including those 
who did (group I; n = 26) and did not (group II; n = 44) undergo donor iliac 
percutaneous transluminal ngioplasty or stent placement, were reviewed. 
Results: No significant differences were found between group I and II patients with respect 
to age, gender, risk factors, surgical indications, preoperative ankle-arm indices, and the 
performance ofassociated procedures. One patient (1.4%) died of a myocardial infarction; 
no other major cardiopulmonary complications occurred. The postoperative change in the 
group I donor limb ankle-brachial index ranged from -0.18 to 0.11 (mean, 0.00), 
revealing no significant steal. The primary graft patency rates for group I and II patients 
30 days after surgery were 92% and 98%, respectively, and at 1, 3, 5, and 7 years after surgery 
were 87% and 81%, 79% and 73%, 79% and 59%, and 66% and 59%. 
Conclusions: Donor iliac artery percutaneous transluminal ngioplasty or stent placement 
dioes not compromise the results of femorofemoral bypass procedures in patients with 
chronic iliac artery occlusive disease. (J Vase Surg 1996;24:363-70 .) 
The extraanatomic femorofemoral bypass (FFB) 
procedure was introduced more than three decades 
ago as a means of providing inflow specifically for 
patients who have unilateral i iac occlusive disease and 
who were not deemed fit to undergo major intraab- 
d0minal reconstructive surgery. 1 Widespread accep- 
tance of this procedure was at least initially limited by 
two fundamental concerns. First, it was argued that in 
view of the progressive nature ofatherosclerosis, new 
disease in the donor iliac artery might significantly 
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compromise long-term graft function. 2 Secondly, it 
was postulated that the recipient limb would steal flow 
from the donor extremity. 3,4 Considerable experience 
accumulated over the past 30 years, however, has 
confirmed that in the absence of significant flow- 
limiting disease in the donor vessel, FFB will provide 
satisfactory early and late results, and the procedure 
has assumed a place in the therapeutic armamen- 
tarium of most vascular surgeons today. 
Most recently, some investigators have argued 
that the indications for the operation should be 
broadened, s,6 Specifically, FFB increasingly is being 
performed in some patients who have bilateral iliac 
disease and in whom the "donor"  iliac artery is 
treated by percutaneous transluminal angioplasty 
(PTA), 6 although it might be logically assumed that 
the issues of progressive donor artery occlusive disease 
and steal would be most relevant in this context. This 
study was therefore undertaken to examine the effi- 
cacy of this approach. 
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PATIENTS AND METHODS 
The records of 70 consecutive patients who un- 
derwent elective FFBs for chronic iliac occlusive 
disease, including those who did (group I, n = 26) or 
did not (group II, n = 44) undergo donor iliac artery 
PTA, stent placement, orboth, by the authors at the 
Johns Hopldns Hospital were retrospectively re- 
viewed. Forty-one were men (58.6%) and 29 were 
women (41.4%), ranging in age from 44 to 82 years 
(mean, 65.9). Arteriosclerotic risk factors and associ- 
ated cardiopulmonary disease were prevalent in this 
patient population and are presented on Table I. As 
noted, group I and II patients were evenly matched 
with respect to age, gender, risk factors, and associ- 
ated major illnesses. 
The indication for operation was intermittent 
clandication i 36 patients (51.4%) and limb-threat- 
ening ischemia in 34 patients (48.6%), including 
ischemic rest pain in 24 (34.3%), nonhealing ulcers in 
four (5.7%), and gangrene in six (8.6%). As noted in 
Table II, the two groups were also evenly matched 
with respect to operative indications, graft material, 
anastomotic sites, and preoperative anlde-brachial 
indexes (ABIs). A synchronous recipient limb infrain- 
guinal bypass grafting procedure was performed in11 
patients (15.7%), including nine (12.8%) femo- 
ropopliteal and two (2.9%) femorotibial grafts. The 
preoperative r cipient-limb ABI ranged from 0.00 to 
0.62 (mean, 0.32 + 0.17) among group I and from 
0.00 to 0.82 (mean, 0.34 + 0.19) among group II 
patients (Table II). 
A total of 32 lesions, including 22 common and 10 
external iliac artery stenoses, underwent endovascular 
treatment among the 26 group I patients. Fifteen 
patients underwent treatment of a single common 
iliac artery lesion (one patient underwent treatment 
of two such lesions); five patients underwent treat- 
ment of both a common and external i iac artery 
lesion; and five patients underwent treatment of a 
single external i iac artery lesion. In three patients, 
diffuse plaque was present hroughout most of the 
donor iliac artery. Although we generally reserve 
angioplasty for focal disease, angioplasty was per- 
formed in these cases because of the patients' ignifi- 
cant risks for aortic reconstruction. The lesions were 
treated by PTA in 20 patients (76.9%) stent place- 
ment, or PTA and stent placement in six patients 
(23.1%). Although our endovascular practice has 
evolved over the 14-year experience, in general stent 
placement was reserved for patients in whom the 
angioplasty result was believed to be suboptimal by 
the interventional radiology team, although most 
recently primary stent placement has been performed. 
The iliac stenosis was treated before surgery in 23 
patients (88.5%), including PTA in 18 (69.2%) pa- 
tients, PTA and Wallstent (1) or PTA and Palmaz 
stent (1) placement in two (7.7%), and primary 
Wallstent (1) or Palmaz stent (2) placement alone in 
three (11.5%). During surgery two patients (7.7%) 
underwent balloon angioplasty, and one patient 
(3.9%) underwent primary Palmaz stent placement. 
The decision to perform donor-limb angioplasty was 
based on the systolic pressure gradient measured 
during the diagnostic arteriogram, and in general if 
the gradient exceeded I0 mm Hg. The systolic 
pressure gradient before treatment ranged from 20 to 
100 mm Hg (mean, 47.5 _+ 18.4 mm Hg); after 
treatment i  ranged from 0 to 51 mm Hg (mean, 
5.6 _+ 4.1 mm Hg). 
RESULTS 
One patient (1.4%) died of a myocardial infarction 
after surgery; no other major cardiopulmonary com- 
plications occurred. Groin infections developed in 
four patients (5.7%), including three in group I and 
one in group II. Wound breakdown was treated with 
dressing changes in one patient in group I and one in 
group II, and with a rotational muscle-flap closure in 
one patient in group I. Wound cellulitis was treated 
with intravenous antibiotics in the other group I 
patient. No grafts were lost acutely to infection. 
Among the group I patientg, two experienced acute 
graft thrombosis at 2 and 14 days after surgery, 
respectively, ielding a 30-day primary graft patency 
rate of 92.3%. Both patients had been considered 
poor candidates for donor iliac artery PTA because of 
diffuse donor iliac artery stenotic disease; they subse- 
quently underwent aortofemoral bypass graft (AFB) 
procedures. There was one graft thrombosis 3 days 
after surgery among the group II patients, yielding a 
30-day primary patency rate of 97.7%. The cause of 
the occlusion was believed to be inadequate outflow, 
and the patient underwent successful thrombectomy 
and a recipient-limb femoropopliteal bypass graft 
procedure. 
Among patients who underwent FFB without 
associated infrainguinal bypass, the recipient-limb 
ABI after surgery ranged from 0.30 to 1.00 (mean, 
0.72 ± 0.22) among group I patients and from 0.33 
to 1.00 (mean, 0.71 ± 0.20) among roup II patients. 
These indexes reflected an increase of 0.12 to 0.59 
(mean, 0.36 __ 0.14) among roup I patients and 0. i2 
to 1.00 (mean, 0.39 __ 0.21) among roup II patients. 
The donor-limb ABI ranged from 0.20 to 1.00 
(mean, 0.64 __ 0.13) before treatment in the group I
patients and from 0.33 to 1.00 (mean, 0.71 ± 0.15) 
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Table I. Patient characteristics 
Group I (n = 26) Group H (n = 44) p 
Men 16 (62%) 25 (57%) NS 
Mean age (yr) 65.6 66.2 NS 
H}qpertension 20 (76.9%) 24 (54.5%) NS 
Diabetes 7 (26.9%) 11 (25.0%) NS 
Hyperlipidemia 3 (11.5%) 3 (6.8%) NS 
Smoking 18 (69.2%) 30 (68.1%) NS 
Cardiac disease 7 (26.9%) 14 (31.8%) NS 
Previous MI 4 (15.4%) 10 (22.7%) NS 
Angina 4 (15.4%) 6 (13.6%) NS 
CHF 3 (11.5%) 4 (9.1%) NS 
COPD 2 (7.7%) 7 (15.9%) NS 
MI, Myocardial infarction; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease. 
Table II. Vascular variables 
Group I (n = 26) Group I I  (n = 44) p 
Indication 
Claudication 14 (53.8%) 22 (50.0%) NS 
Rest paln 9 (34.6%) 15 (34.1%) NS 
Nonhealing ulcer 2 (7.7%) 2 (4.5%) NS 
Gangrene 1 (3.8%) 5 (11.4%) NS 
Graft material (n = 69) 
Dacron 25 (96.2%) 36 (83.7%) NS 
PTFE 1 (3.8%) 7 (16.3%) NS 
Proximal anastomosis (n = 69) 
C]FA 26 (100.0%) 38 (88.4%) NS 
Graft - -  5 (11.6%) NS 
Distal anastomosis (n = 69) 
CFA 7 (26.9%) 9 (20.9%) NS 
SFA 5 (19.2%) 15 (34.9%) NS 
Profunda femoris 14 (53.8%) 19 (44.2%) NS 
Recipient limb 
Mean ABI 0.32 + 0.17 0.34 + 0.19 NS 
Infrainguinal bypass 3 (11.5%) 8 (18.1%) NS 
PTFE, Polytetrafluoroethylene; CFA, common femoral artery; SFA, superficial femoral artery. 
after surgery. The postoperative change in donor- 
limb ABI ranged from -0.18 to 0.11 (mean, 0.00) 
among group I patients. Specifically, the index in- 
creased from 0.04 to 0.11 in 57% of the patients and 
decreased from 0.05 to 0.18 in 43%. Among the 
group II patients, the donor-limb ankle-arm index 
ranged from 0.25 to 1.00 (mean, 0.73 + 0.23) before 
surgery and from 0.35 to 1.00 (mean, 0.69 + 0.18) 
after surgery. This reflected a change in the donor- 
limb ankle-arm index ranging from -0.28 to 0.25 
(mean, -0.13). Specifically, the index increased from 
0.01 to 0.2', 5 in 44% of the patients and decreased from 
0.01 to 0.2,8 in 56%. In other words, reduction in the 
donor-limb ABI was not more likely to occur in group 
I patients than in patients from group II. 
Follow-up has ranged from 1 to i39 months 
(mean, 39 months) among the group I patients. 
Three additional grafts have occluded at 5, 27, and 72 
months (mean, 37 months) after surgery. The graft 
failure at 5 months was a result of progressive iliac 
disease in a patient who was recognized to be a 
relatively unfavorable PTA candidate because of dif- 
fuse donor iliac artery occlusive disease. The two 
other failures were believed to be caused by progres- 
sive recipient-limb outflow disease. With life-table 
analysis, the primary graft patcncy rate was 87% at I 
year, 79% at 3 years, 79% at 5 years, and 66% at 7 years 
(Table III). Among the group II cases, follow-up 
ranged from 1 to 108 months (mean, 2I months). In 
addition to the acute postoperative graft thrombosis, 
six grafts have occluded at 6, 6, 8, 8, 33, and 63 
months after surgery (mean, 20.7 months). The 
causes of graft thrombosis were progressive recipient 
outflow disease in two patients and progressive donor 
iliac disease in three; the cause could not be deter- 
mined from the record in one case. Hemodynamic 
graft failure developed in two additional patients as a 
result of progressive donor iliac disease 9 and 11 
months after surgery; the patients underwent revision 
with axillofemoral and AFB, respectively. With life- 
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Table III. Life-table FFB primary patency rates 
Time (yr) At  risk Occluded Lost Patency rate SE 
All cases 0-1 26 3 6 0.870 0.062 
Group I 1-2 17 0 4 0.870 0.076 
2-3 13 1 4 0.791 0.100 
3-4 8 0 2 0.791 0.128 
4-5 6 0 0 0.791 0.148 
5-6 6 1 0 0.659 0.157 
6-7 5 0 2 0.659 0.172 
Group II 0-1 44 7 15 0.808 0.053 
1-2 22 0 9 0.808 0.075 
2-3 13 1 4 0.734 0.105 
3-4 8 0 2 0.734 0.134 
4-5 6 1 2 0.587 0.154 
5-6 3 0 2 0.587 0.217 
6-7 1 0 0 0.587 0.377 
No IIBPG 0-1 22 3 8 0.833 0.072 
Group I 1-2 11 0 1 0.833 0.102 
2-3 10 1 4 0.723 0.119 
3-4 5 0 2 0.723 0.170 
4-5 3 0 0 0.723 0.194 
5-6 3 1 0 0.482 0.200 
6-7 2 0 0 0.482 0.245 
Group II 0-1 35 3 13 0.895 0.049 
1-2 19 0 8 0.895 0.067 
2-3 11 1 4 0.796 0.108 
3-4 6 0 0 0.796 0.147 
4-5 6 1 2 0.637 0.157 
5-6 3 0 2 0.637 0.222 
6-7 1 0 0 0.637 0.384 
IIBPG, Associated infrainguinal bypass graft. 
table analysis the primary graft patency rate was 81% 
at 1 year, 73% at 3 years, 59% at 5 years, and 59% at 7 
years (Table III). No significant difference was found 
by log rank analysis in primary patency between group 
I and group II patients, although the standard error 
exceeded 10% after 3 years. Furthermore, when 
patients who underwent recipient-limb infrainguinal 
bypass grafting procedures were excluded from the 
analysis, the primary graft patency rates for group I 
and II patients, respectively, were 83% and 90% at 1 
year, 72% and 80% at 3 years, 72% and 64% at 5 years, 
and 48% and 64% at 7 years (Table III). These 
differences were not significantly different by log rank 
analysis, although the standard error exceeded 10% 
after 2 years. 
DISCUSSION 
Over the past decade several reports have docu- 
mented remarkably consistent 5-year FFB primary 
patency rates, ranging from 55% to 63%. 6-n Two 
recent studies, including more than 300 cases, have 
reported cumulative patency rates of 92% at 6 years 
and 86% at 13 years, respectively, s,9Furthermore, 
several large series published over the past decade have 
documented operative mortality rates ranging from 
0% to 6.2%) '8-13 As in the current report, a periop- 
erative myocardial infarction was the most frequent 
cause of death, s'8,n It seems clear that in properly 
selected patients FFB can provide reasonable long- 
term patency rates with minimal operative risk. 
The first two cases of donor iliac artery PTA and 
FFB were reported more than 20 years ago, with graft 
patency at 14 and 18 months, respectively. 14 This 
approach subsequently has been reported from sev- 
eral other centers. 7-9,11,1s-21 Unfortunately, much of 
this experience is anecdotal, patency data has not been 
reported in some series, and long-term follow-up has 
been limited (Table IV). For example, in the largest 
series reported to date, donor iliac artery PTA was 
performed in 40 of 156 cases of FFB (25.5%), but the 
patency rate was not specifically documented for this 
subset. 9 In another series of 31 cases, the cumulative 
graft patency rate at 3 years was 83%. 20 Schneider et 
al.7 reported eight cases with a 3-year primary patency 
rate of only 42%. In fact, only two previous reports 
that included at least 20 patients have actually docu- 
mented primary graft patency rates, and the results 
have been somewhat conflicting. Criado et al.n re- 
ported a 1-year primary graft patency rate of 78% 
among 24 cases in which the donor iliac artery 
underwent PTA, as opposed to a patency rate of 91% 
among patients in whom PTA was not performed. 
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Table IV. Donor iliac PTA and FFB: reported results 
Source Year No. of cases Patency rate Follow-up 
Porter et al. 14 1973 2 100" 6, 8 mo 
Howell et al. 1~ 1983 3 100" <8 mo 
Corey et al. 16 1983 6 NA NA 
Pfeiffer et al. ~7 1986 8 NA NA 
Brewster et al. TM 1989 18 NA NA 
Peterkin et al. 19 1990 20 83* 5 yr 
Walker et al. 2° 1991 31 81 3 yr 
Harfington et al. s 1992 24 NA NA 
Shah et al. 2~ 1992 22 91 3.5 yr 
Ng et al. 9 1992 40 NA NA 
Criado et al. n 1993 24 78* 1 yr 
Schneider et al. 7 1994 8 42* 3 yr 
Present series 26 66* 7 yr 
*Primary patency rate. 
This difference, however, was not statistically signifi- 
cant. In addition, Peterkin et al.19 reported a 5-year 
primary patency rate of 83% among 20 cases. Our 
series provides the longest follow-up to date for this 
approach, and the results are consistent with the study 
of Peterkin et al. 
Our experience reflects the sound rationale on 
which thi,; intervention has been undertaken. PTA is 
well accepted as a safe and effective treatment for focal 
iliac artery stenoses. In a metaanalysis ofnearly 3000 
cases ofiliac artery angioplasty, the initial success rate 
was 92% and the 5-year patency rate was 72%. 22 In 
addition, early experience suggests that iliac artery 
stenting may result in superior patency rates, either as 
an adjunc.t o angioplasty, or as primary therapy. 23 
Although this approach clearly highlights the poten- 
tial for recurrent iliac artery disease to compromise 
long-term graft patency rates, graft occlusion infre- 
quently re.sults from progressive inflow disease in the 
absence of donor iliac artery PTA. Lamerton et al. 13 
reported that only one of 54 FFBs (2%) failed as a 
result of progressive donor iliac artery occlusive 
disease, 13 and in another report only one of 113 FFBs 
(1%) failed as a result of progressive inflow disease. 24 
In a recent multicenter study, progressive donor iliac 
artery occlusive disease that required either PTA or 
surgical reconstruction developed in only 6% of 317 
patients who underwent FFB, with a mean follow-up 
of 38 months. 25 Our series is consistent with this 
experience. Although two acute and one long-term 
graft hromboses were attributed to donor iliac artery 
disease among the group I cases, each of these patients 
had been recognized as anatomically suboptimal 
angioplasty candidates, but were so treated in hopes 
of avoiding aortic reconstruction caused by significant 
comorbid conditions. Even when less-than-satisfac- 
tory angioplasty cases were included in the analysis, 
however, we found that donor iliac artery angioplasty 
did not adversely affect short-term or long-term graft 
patency rates. 
In fact, one might postulate that by enhancing 
outflow FFB might actually retard isease progression 
in the donor artery, and specifically, recurrent disease 
at the angioplasty site. 26'27 In a classic experimental 
model, Ehrenfeld et al?s noted that flow through the 
canine iliac artery doubled after construction of a 
crossover femoral graft as a result of the decreased 
peripheral resistance associated with the bypass. It has 
been suggested that this decrease in peripheral resis- 
tance could lead to dilatation of the proximal vessel, as 
is seen in the setting of an arteriovenous fi tula. 29,3° To 
investigate this hypothesis, da Gama 31 obtained fol- 
low-up arteriograms of 18 patients from 8 to 57 
months after FFB (mean, 18 months) and compared 
them with the preoperative arteriograms. A modest 
increase in the diameters of the dono? external i iac 
and common femoral arteries was documented in all 
18 cases. 
This report raises everal issues that remain unre- 
solved. Because only stenotic lesions were treated, 
we cannot speculate on the long-term results of FFB 
based on recanalized complete iliac artery occlu- 
sions. Previous work has clearly demonstrated infe- 
rior patency rates associated with angioplasty of com- 
plete occlusions when compared with stenotic le- 
sions. 22'32'33 For example, in the report of Johnston et 
al.32 the 5-year success rates of common iliac artery 
PTA of stenotic and occlusive lesions, respectively, 
were 63% and 48% with good run-off and 51% and 
33% with poor run-off. We therefore believe that AFB 
remains the revascularization ption of choice for all 
but the most exceptional patient with bilateral iliac 
artery occlusions. Secondly, although the number of 
cases in this series is too small to allow meaningful 
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subset analysis, on the basis of previous work we 
would anticipate somewhat inferior long-term graft 
patency rates when FFB is based on a dilated external, 
as opposed to common, iliac artery. 32,33 In one recent 
study, for example, the 3-year success rate for 313 
common iliac artery PTA procedures was 68%, as 
opposed to 57% for men and 34% for women who 
underwent 204 external iliac artery PTA proce- 
dures? 3 In addition, our limited stent experience 
precludes making dogmatic predictions about the 
impact of this technology on the role of FFB in 
managing patients who have bilateral iliac artery 
occlusive disease. 
Finally, in view of the superior imaging capability, 
other logistical concerns, and to allow a period of 
observation of the hemodynamic result of the angio- 
plasty, our preference has been to have the iliac 
angioplasty performed in the angiography depart- 
ment, typically 24 to 48 hours before surgery, as 
others have suggested. 18 On the other hand, if suit- 
able fluoroscopic equipment is available, endovascular 
treatment at the time of the surgical bypass grafting 
procedure is acceptable, and indeed may prove to be 
a more cost-efficient approach. 16,17 
CONCLUSION 
In view of the dramatic aging of our population, 
vascular surgeons will be seeing an increasing number 
of patients who have significant peripheral ischemia 
and other comorbid conditions. FFB is an appropriate 
method of achieving unilateral inflow reconstruction 
in this patient population. Our study suggests that this 
extraanatomic form of revascularization may also be 
performed with minimal risk and acceptable patency 
rates in selected patients with bilateral disease. In our 
practice today, this approach is undertaken in patients 
who have bilateral iliac occlusive disease if the occlu- 
sive process in the proposed donor iliac artery is focal 
and amenable to endovascular correction, and if the 
patient is not deemed to be a candidate for AFB. 
However, we continue to perform AFB in the major- 
ity of patients who have bilateral inflow disease. 
Although endovascular practice has evolved signifi- 
cantly over the 14-year experience, in general stent 
placement has been reserved for suboptimal angio- 
plasty results, although more recently primary stent 
placement has been increasingly practiced. 
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DISCUSSION 
Dr. Jock R. Wheeler (Norfolk, Va.). Does donor iliac 
artery PTA or stenting influence the results of FFB? As has 
been pointed out, this is sometimes considered a marginal 
operation i  the first placc, and I wonder in looking through 
this particular study that only 30% of the patients howed 
significant cardiac disease. What is thc real indication for 
doing FFB, particularly with this low incidence of cardiac 
disease, and would some of these younger patients have 
done better with a primary AFB graft? 
It is also noted that approximately one half of these 
patients were operated on for ischemia nd not for claudi- 
cation, but the run-offstatus was not clarified, and I wonder 
how did this influence what you did? 
In this study only six patients underwent a combined 
PTA and stent procedure. Arc you now using this procedure 
more often, and if so are you doing it in the operating room 
or is it being done by the radiologist ahead of time? 
Your thoughts would be appreciated about he increas- 
ing use of this operation ow that we have stents and PTA 
being used extensively. Are we therefore pursuing an 
inferior operation and using endovascular techniques? Is
this a money saving consideration? 
Lastly, I 'd like to read to you very briefly a little quote, 
" In the presence of unilateral iliac artery occlusion and 
limited contralateral iliac stenosis, pcrcutaneous translumi- 
nal angioplasty of the stenotic iliac artery can provide 
adequate donor femoral inflow to permit femorofemoral 
bypass. Patency with this combined approach iscomparable 
to that with femorofemoral bypass in the absence of donor 
iliac artery stenosis." This quote comes from a textbook by 
our honored guest lecturer, who I hope will comment on 
this paper. 
Dr. Bruce A. Perler. I 'd like to thank Dr. Wheeler for 
his questions and I'll try to respond to them in order. This 
study had one purpose: to answer the question of whether 
angioplasty of the donor iliac artery compromises FFB 
results, and I think we have fairly adequately answered that 
question within the limitations of a retrospective study. He 
asked about the real indications for AFB and might not 
some of the younger patients have been better served by 
AFB grafting. We perform FFBs infrequently and combine 
it with iliac angioplasty even less often. In reviewing this 
series rctrospectively, in each case there were specific reasons 
why this strategy was pursued. For example, among two of 
the three so-called "poor-risk" patients in whom angio- 
plasty was nevertheless performed espite the donor iliac 
artery being rclatively unfavorable for angioplasty, one 
patient had perforated diverticulitis, underwent a resection 
and colostomy, and had a severely ischemic foot. The hope 
was to dilate the better of the two bad iliac arteries, perform 
the FFB, and provide the patient afew months of ischemic 
symptom relief. Another patient had a severely ischemic 
foot, was noted to have guaiac-positive stools, and found to 
have a large colon tumor. The hope was to do the extraana- 
tomic bypass o he could then undergo his colonic opera- 
tion during that admission and at least buy him some time 
with the FFB graft. 
Clearly, I don't think anybody should interpret this data 
as a challenge to the preeminence of AFB as the optimal 
approach for bilateral aortoiliac occlusive disease. It cer- 
tainly is the most frequently performed operation in our 
hospital for that purpose today, as it has been for years, 
although as I think many of you recognize that it is being 
performed less frequently with the growth of endovascular 
therapy. Among younger patients who have truly unilateral 
iliac disease, FFB is still an option that will provide good 
long-term results while avoiding the potential complica- 
tions of aortic reconstruction. We do see older patients 
today who for one reason or another may not be ideal 
candidates for aortic surgery. For example, when I finished 
my training, I thought 65 years was old. Now when I see 
65-year-olds inmy clinic, often they are there bringing their 
88- and 90-year-old parents for their visits, so I think we 
need to have a number of options available to treat this 
elderly patient population. I think that this is one potential 
option for them. 
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The question of runoff was raised. We didn't specifically 
analyze the runoff in these patients, because it was difficult 
in some of these cases to get that much detail, with the 
angiographic information spanning back 14 years. 
We perform these procedures collaboratively with our 
interventional radiologists. Specifically, most of them have 
been done by the radiologists in the catheterization labo- 
ratory before surgery, and this has really been a function 
of our equipment limitation because we have only had a 
portable C-arm, which doesn't allow optimal intraopera- 
tive therapy. However, we are currently acquiring state- 
of-the-art echnology that will allow road mapping and 
better imaging during surgery, so I expect hat many more 
of these procedures will be done in the operating room 
in the future. But again, we will perform them with our 
interventional radiologists with whom we have a very 
collegial and I think mutually beneficial cooperative ar- 
rangement. 
Dr. Robert  Rutherford (Denver, Colo.). We have 
been following the same policy of dilating the donor 
iliac artery if we had a discrete common iliac stenosis. We 
don't have as many as you do, but our data suggest hat 
this did not compromise the patency of the FFB. As we 
became more aggressive with this, however, and started 
doing external i iac dilations, and particularly dilations of 
lesions right at the bifurcation of the iliac artery, we found 
that the results were less favorable. I notice that you had 
some cases with external iliac stenosis. Did you see a 
difference in outcome between those cases and common 
iliac stenoses? 
Dr. Perler. In a series of 26 patients who underwent 
angioplasty, it is difficult to perform a meaningful subset 
analysis. Having said that, three of the graft occlusions 
occurred among the 16 patients who had undergone 
angioplasty of one or two common iliac artery lesions. Of 
the five patients who had both a common and external i iac 
artery lesion dilated, there were two graft failures, and the 
other graft failure in the angiography group occurred 
among the five patients who had external iliac artery lesions 
dilated. Therefore, we get the sense, and it is as one would 
expect based on the superior track record of common versus 
external iliac angioplasty, that one will get the best results in 
dilating a focal, relatively short common iliac artery lesion, 
as Dr. Rutherford has pointed out. 
We also have the sense that the FFB operation may be 
protective to that angioplasty site. Previous experimental 
work in the animal model demonstrated that as much as 
doubling ofiliac flow occurs by creating adistal fistula, and 
I think that by performing an FFB and increasing outflow 
we increase flow velocity through that iliac system, which 
may be somewhat protective to the angioplasty site. There 
was one very interesting report in the Journal of Vascular 
Surgery several years ago from Lisbon in which 18 patients 
who had undergone FFBs were studied with angiography an 
average of about 3 years after the bypass, and the angio- 
grams from before and after the bypass procedure were 
compared to look at iliac artery diameters. In each of those 
18 patients, they could demonstrate varying degrees of 
dilatation of the donor iliac system, so we may be helping 
out our radiologists in terms of overall patency of the iliac 
angioplasties by performing the FFB. 
Dr. Luis A. Queral (Baltimore, Md.). We have been 
performing angioplasty and stenting in the operating room 
for a number of years, and I specifically wanted to state that 
the external i iac artery is a very different artery from the 
common iliac inasmuch as the lesions are rarely focal. They 
are quite extensive and therefore much more amenable to an 
endarterectomy or stenting. Just a balloon angioplasty has 
been shown in the external iliac artery to not be a very good 
inflow-type procedure. I also wanted to ask you a question 
regarding the follow-up of these patients in the blood-flow 
laboratory. We have found in our series that failing bypasses 
are salvageable with repeat angioplasty and stenting in the 
common iliac sector when the problem is in inflow, and this 
is detected on duplex scanning. I am wondering if that 
would not have improved the patency of your bypasses that 
failed from a restenosis of the inflow area. 
Dr. Perler. I agree with both of your comments. Again, 
this series went back more than a decade, and we weren't 
doing routine surveillance. Typically, our followup of FFB 
patients was clinical with associated ankle-arm indices. 
Today, color flow duplex imaging of those iliac lesions may 
be a very reasonable way to salvage an occasional FFB graft 
due to a failing angioplasty site. 
